Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Changpu Yujin Tang is a Traditional Chinese Medicine (TCM) herbal formulation developed and utilized by researchers at Tianjin Huanhu Hospital for the treatment of convulsive status epilepticus (CSE). The formula is a modification of the classic Changpu Yujin Tang, which traditionally contains *Acorus tatarinowii* (Shichangpu) and *Curcuma aromatica* (Yujin). In the context of CSE, the modification typically involves the addition of herbs such as *Arisaema cum Bile* (Dan Nan Xing) and *Bambusae Caulis in Taeniam* (Zhu Ru) to enhance its ability to clear heat, resolve phlegm, and open the orifices. Pharmacologically, the decoction is thought to exert anticonvulsant and neuroprotective effects by modulating neurotransmitter systems—specifically increasing GABAergic inhibition and reducing glutamatergic excitotoxicity—and by suppressing neuroinflammatory cytokines like IL-6 and TNF-alpha. It is generally administered as an adjunctive therapy alongside standard Western anti-epileptic drugs to improve consciousness recovery and reduce seizure recurrence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified Changpu Yujin Tang.